Antigen-specific immune tolerance could redefine autoimmune disease treatment by precisely retraining the immune system rather than broadly suppressing it.
- Are Biopharma Companies Outsourcing Their Ability To Think?
- June 2026 — CDMO Opportunities And Threats Report
- The Decision Rights Matrix: Making Sponsor-CDMO Governance Enforceable
- Defining Quality In A Sponsor-Owned QTPP Before The CDMO Even Starts
- ImvivaBio's Trial For Off-The-Shelf CAR-T Strategy For Aggressive Malignancies
- Reshoring Pressure Meets Manufacturing Reality
- CDMO Live Europe 2026: Partnerships For An Uncertain World
- Resilience, Risk, And Relationships: CDMO Live Europe 2026 Report
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
In Vivo RNA Tuning For Liver Gene Editing Efficiency
RNA sequence and guide modifications, delivery platform design, and dose optimization all contribute to improved gene editing outcomes, which offers a clearer path toward safer, more potent, and scalable mRNA-based therapeutics.
-
Virus Reduction And Impurity Removal
Examine a DOE-based study that reveals how buffer conditions impact virus and impurity clearance using a mixed-mode resin, as well as gain practical guidance for optimizing downstream purification.
-
A Duplex Assay For Quantification And Qualification Of AAV
Adeno-associated virus is a key gene therapy vector. Explore how digital PCR offers precise, standard-free quantification with improved consistency and inhibitor tolerance over traditional qPCR methods.
-
Ready To Demystify Organoids?
Organoids are transforming biomedical research. Explore their top applications, research workflows, key challenges, and dissociation techniques in this comprehensive guide to personalized medicine.
-
Driving Digital Excellence In Life Sciences
The life sciences industry is rapidly evolving through digital transformation and agility. Discover why embracing modern technologies is essential to thrive in today’s competitive landscape.
-
Rescuing A Global Program For NDA Success
Explore the collaboration that enabled FDA approval of a novel chronic-condition therapy, rescued a high-risk program, and demonstrated a unified “one-team” approach by reworking the sponsor's SAP.
-
Automated Library Prep For A Nanopore DNA Barcoding Protocol
A streamlined workflow reduces reagent use and hands‑on time while preserving long‑read sequencing quality. See how multiplexed offer an efficient option for scaling or mobilizing sequencing efforts.
-
Rescuing A Global Full-Service Phase III Trial For A Late-Stage Oncology Biotech
This case underscores the expertise employed in a comprehensive strategy and set of services that were used to salvage a Phase III clinical trial for ovarian cancer and ensure its timely completion.
-
Three-Dimensional Linkage Analysis With Digital PCR For Genome Integrity
A cost-effective approach with a comprehensive AAV analytical package holds the potential to advance the application of rAAV in cell and gene therapy for the treatment of human diseases.
-
Application Of A Dual Spiking Strategy In Viral Clearance Studies
Explore how an alternative spiking strategy can streamline viral clearance studies, reduce material demands, and maintain compliance while addressing the challenges posed by MLV and MMV.
NEWSLETTER ARCHIVE
- 08.12.26 -- Tariffs, FDA Chaos, And BioSecure: How CDMOs Should Operate
- 08.11.26 -- When Innovation Meets Scale
- 08.11.26 -- Rewriting The Playbook For Stargardt Disease With Atsena Therapeutics' Shannon Boye, Ph.D.
- 08.11.26 -- Solving Vector Yield Challenges Starts Long Before Manufacturing
- 08.10.26 -- Modern Tools For High-Yield Biomanufacturing
- Building Antigen-Specific Immune Tolerance For Autoimmune Disease
- Solving Vector Yield Challenges Starts Long Before Manufacturing
- Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors
- FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy
- How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections